BRICHANT, Géraldine ; Centre Hospitalier Universitaire de Liège - CHU > Département de gynécologie-obstétrique > Service de gynécologie-obstétrique (CHR)
NECHIFOR - POTORAC, Iulia ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'endocrinologie clinique
PETIGNOT, Sandrine ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'endocrinologie clinique
TEBACHE, Linda ; Centre Hospitalier Universitaire de Liège - CHU > Département de gynécologie-obstétrique > Service de gynécologie-obstétrique (CHR)
Pintiaux, Axelle ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
NISOLLE, Michelle ; Centre Hospitalier Universitaire de Liège - CHU > Département de gynécologie-obstétrique > Service de gynécologie-obstétrique (CHR)
Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Language :
French
Title :
Le syndrome des ovaires micropolykystiques : L'avantage d'une prise en charge multidisciplinaire
Alternative titles :
[en] Polycystic ovary syndrome : the advantages of multidisciplinary management
Publication date :
2020
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian morphology : a task force report from the androgen excess and polycystic ovary syndrome society. Hum Reprod Update 2014; 20:334-52.
Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29:181-91.
Escobar-Morreale HF, Millán JLS. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007; 18:266-72.
Dumesic DA, Oberfield SE, Stener-Victorin E, et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev 2015; 36:487-525.
Ciampelli M, Fulghesu AM, Cucinelli F, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 1999; 48:167-72.
Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97:28-38.
Fauser BC. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25.
Rosenfield RL. The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics 2015; 136:1154-65.
Lie Fong S, Laven JSE, Duhamel A, Dewailly D. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome : redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis. Hum Reprod 2017; 32:1723-31.
Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91:456-88.
Pasquali R, Zanotti L, Fanelli F, et al. Defining hyperandrogenism in women with polycystic ovary syndrome : a challenging perspective. J Clin Endocrinol Metab 2016; 101:2013-22.
Isojarvi J, Laatikainen TJ, Pakarinen AJ, Myllyla V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329:1383-8.
Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004; 145:799-808.
Wood JR, Nelson-Degrave VL, Jansen E, et al. Valproateinduced alterations in human theca cell gene expression: Clues to the association between valproate use and metabolic side effects. Physiol Genomics 2005; 20:233-43.
Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome : a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. J Clin Endocrinol Metab 2010; 95:2038-49.
Fernandez RC, Moore M, van Ryswyk M, et al. Sleep disturbances in women with polycystic ovary syndrome : prevalence, pathophysiology, impact and management strategies. Nat Sci Sleep 2018; 10:45-64.
Balen AH, Conway GS, Kaltsas G, et al. Andrology : polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995; 10:2107-11.
Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12:673-83.
Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: Results of a 31 year follow-up study. Hum Fertil 2000; 3:101-5.
Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 2012; 27:1327-31.
Li Y, Li Y, Yu Ng EH, et al. Polycystic ovary syndrome is associated with negatively variable impacts on domains of healthrelated quality of life: Evidence from a meta-analysis. Fertil Steril 2011; 96:452-8.
Kaczmarek C, Haller DM, Yaron M. Health-Related quality of life in adolescents and young adults with polycystic ovary syndrome : a systematic review. J Pediatr Adolesc Gynecol 2016; 29:551-7.
Jones GL, Hall JM, Balen AH, Ledger WL. Health-related quality of life measurement in women with polycystic ovary syndrome: A systematic review. Hum Reprod Update 2008; 14:15-25.
Moran LJ, Pasquali R, Teede HJ, et al. Treatment of obesity in polycystic ovary syndrome : a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 2009; 92:1966-82.
Palomba S, Falbo A, Zullo F, Orio F. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome : a comprehensive review. Endocr Rev 2009; 30:1-50.
Naderpoor N, Shorakae S, De Courten B, et al. Metformin and lifestyle modification in polycystic ovary syndrome: Systematic review and meta-analysis. Hum Reprod Update 2015; 21:560-74.
Genazzani AD. Inositol as putative integrative treatment for PCOS. Reprod Biomed Online 2016; 33:770-80.
Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340:1314-20.
Iuorno MJ, Jakubowicz DJ, Baillargeon JP, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002; 8:417-23.
Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myoinositol in women with PCOS : a systematic review of randomized controlled trials. Gynecol Endocrinol 2012; 28:509-15.
